Isentress is an antiretroviral medication used to treat hiv infection. Its active ingredient is raltegravir, which belongs to the class of integrase inhibitors. The drug works by binding to the hiv integrase enzyme and preventing the integration of viral dna into host cell genomes. This inhibition blocks a crucial step in the viral replication cycle, limiting the ability of the virus to establish persistent infection. By reducing viral replication, Isentress helps maintain lower viral loads and supports immune function in patients. The pharmacological process involves selective interaction with the catalytic site of integrase, leading to a reversible inhibition that does not interfere with normal cellular dna processes. Consequently the medication contributes to the overall control of hiv without directly targeting uninfected cells.

Isentress is an antiretroviral medication used in the treatment of hiv infection. It belongs to a class of drugs called integrase inhibitors that block the viral enzyme integrase. By inhibiting integrase the virus cannot insert its genetic material into the host cell's dna. This prevents the formation of new infectious virions and reduces viral replication. The active ingredient in Isentress is raltegravir a synthetic compound that binds tightly to the integrase active site. Binding blocks the enzyme's ability to catalyze the strand transfer step of the viral life cycle. As a result the infected cell cannot produce mature virus particles and the spread of infection is limited. Isentress therefore helps control hiv disease progression when used as part of a combination therapy.

Isentress may cause nausea or a loss of appetite in some patients. Headache and dizziness are also reported side effects. Fatigue and general weakness can occur during treatment. Skin reactions such as rash or itching may develop. Some individuals experience difficulty sleeping or vivid dreams. Elevated liver enzymes have been observed in laboratory tests. Patients sometimes notice changes in taste perception or dry mouth. Increased bilirubin levels can lead to mild yellowing of the skin or eyes.

Isentress may cause mild headache and nausea in some patients. It can occasionally lead to insomnia or difficulty sleeping. Some individuals experience mild skin rash or itching. Elevated liver enzymes have been reported in rare cases. Patients may notice temporary changes in taste sensation. Fatigue or mild weakness can occur during treatment. Occasional dizziness has been observed in clinical studies. Most side effects are mild and often resolve without intervention.